Faster clinical decisions in B‐cell acute lymphoblastic leukaemia: A single flow cytometric 12‐colour tube improves diagnosis and minimal residual disease follow‐up

Summary Assessing minimal residual disease (MRD) in B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL) is essential for adjusting therapeutic strategies and predicting relapse. Quantitative polymerase chain reaction (qPCR) is the gold standard for MRD. Alternatively, flow cytometry is a quicke...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2024-05, Vol.204 (5), p.1872-1881
Main Authors: Lebecque, Benjamin, Besombes, Joevin, Dannus, Louis‐Thomas, De Antonio, Marie, Cacheux, Victoria, Grèze, Victoria, Montagnon, Valentin, Veronese, Lauren, Tchirkov, Andrei, Tournilhac, Olivier, Berger, Marc G., Veyrat‐Masson, Richard
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Antigens, CD - analysis
BCP‐ALL
CD43 antigen
CD73 antigen
CD81 antigen
Cell differentiation
Child
Child, Preschool
Clinical Decision-Making
Diagnosis
Female
Flow cytometry
Flow Cytometry - methods
Follow-Up Studies
Humans
Immunophenotyping - methods
Leukemia
Lysis
Male
Minimal residual disease
Neoplasm, Residual - diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - diagnosis
Principal components analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Assessing minimal residual disease (MRD) in B‐cell precursor acute lymphoblastic leukaemia (BCP‐ALL) is essential for adjusting therapeutic strategies and predicting relapse. Quantitative polymerase chain reaction (qPCR) is the gold standard for MRD. Alternatively, flow cytometry is a quicker and cost‐effective method that typically uses leukaemia‐associated immunophenotype (LAIP) or different‐from‐normal (DFN) approaches for MRD assessment. This study describes an optimized 12‐colour flow cytometry antibody panel designed for BCP‐ALL diagnosis and MRD monitoring in a single tube. This method robustly differentiated hematogones and BCP‐ALL cells using two specific markers: CD43 and CD81. These and other markers (e.g. CD73, CD66c and CD49f) enhanced the specificity of BCP‐ALL cell detection. This innovative approach, based on a dual DFN/LAIP strategy with a principal component analysis method, can be used for all patients and enables MRD analysis even in the absence of a diagnostic sample. The robustness of our method for MRD monitoring was confirmed by the strong correlation (r = 0.87) with the qPCR results. Moreover, it simplifies and accelerates the preanalytical process through the use of a stain/lysis/wash method within a single tube (
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.19390